# Early intestinal barrier changes in A53T transgenic Parkinson’s disease mice

**Authors:** Myat Noe Han, Olivia Artaiz, Matthew C. Rowe, David I. Finkelstein, Shanti Diwakarla, Rachel M. McQuade

PMC · DOI: 10.1007/s00441-026-04062-9 · 2026-03-24

## TL;DR

This study shows that gut barrier issues appear before brain changes in a mouse model of Parkinson’s disease, suggesting the gut could be an early target for treatment.

## Contribution

The study identifies early intestinal barrier dysfunction in A53T transgenic mice before CNS pathology, offering new insights into Parkinson’s disease progression.

## Key findings

- A53T mice showed increased intestinal permeability at 12 and 36 weeks.
- Early reductions in Claudin-1 and altered mucin expression were observed in the ileum and colon.
- Gut dysfunction occurred before central nervous system changes in the PD mouse model.

## Abstract

Gut dysfunction commonly precedes motor symptoms in Parkinson’s disease (PD), but the mechanistic sequence of gut versus brain pathology remains unclear. This work aimed to define the timing of intestinal barrier dysfunction relative to central nervous system (CNS) changes in the A53T α-synuclein transgenic mouse model of PD. Functional and molecular assessments of the gastrointestinal tract (ileum and colon) were conducted at 12 and 36 weeks. We measured in vivo and ex vivo intestinal permeability, nutrient absorption, histomorphology, goblet cell density, and expression of MUC2 and Claudin-1. Inflammatory markers (CRP, TNF-α, CD45) were quantified in plasma and gut tissues. A53T mice exhibited increased intestinal permeability at 12 and 36 weeks, with transiently elevated ex vivo transepithelial electrical resistance (TER) at 12 weeks. Nutrient absorption remained intact. Morphological changes included widened villi and crypts, altered mucin expression, and early reductions in Claudin-1 in the ileum and the colon while inflammatory markers remained largely unchanged. These findings suggest that gut dysfunction precedes known central pathology in A53T mice, supporting further investigation into the gut as an early site of pathology and a potential therapeutic target in PD.

The online version contains supplementary material available at 10.1007/s00441-026-04062-9.

## Linked entities

- **Genes:** MUC2 (mucin 2, oligomeric mucus/gel-forming) [NCBI Gene 4583], CLDN7 (claudin 7) [NCBI Gene 1366], CRP (C-reactive protein) [NCBI Gene 1401], TNF (tumor necrosis factor) [NCBI Gene 7124], PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788]
- **Diseases:** Parkinson’s disease (MONDO:0005180)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** CLDN1 (claudin 1) [NCBI Gene 9076] {aka CLD1, ILVASC, SEMP1}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, Hp (haptoglobin) [NCBI Gene 15439] {aka HP-1, preHP2}, Tjp1 (tight junction protein 1) [NCBI Gene 21872] {aka ZO1}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Prnp (prion protein) [NCBI Gene 19122] {aka CD230, PrP, PrP<C>, PrPC, PrPSc, Prn-i}, EPCAM (epithelial cell adhesion molecule) [NCBI Gene 4072] {aka Ber-Ep4, BerEp4, DIAR5, EGP-2, EGP314, EGP40}, Uchl1 (ubiquitin carboxy-terminal hydrolase L1) [NCBI Gene 22223] {aka PGP 9.5, PGP9.5, UCH-L1, UCHL-1, gad}, Crp (C-reactive protein, pentraxin-related) [NCBI Gene 12944], Gfap (glial fibrillary acidic protein) [NCBI Gene 14580], SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}, Muc2 (mucin 2) [NCBI Gene 17831] {aka 2010015E03Rik, MCM, wnn}, Epcam (epithelial cell adhesion molecule) [NCBI Gene 17075] {aka CD326, EGP, EGP-2, Egp314, Ep-CAM, EpCAM1}, Lbp (lipopolysaccharide binding protein) [NCBI Gene 16803] {aka Bpifd2, Ly88}, TJP1 (tight junction protein 1) [NCBI Gene 7082] {aka ZO-1}, Cldn1 (claudin 1) [NCBI Gene 12737], Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Mucin [NCBI Gene 100508689], Snca (synuclein, alpha) [NCBI Gene 20617] {aka NACP, alpha-Syn, alphaSYN}, MUC2 (mucin 2, oligomeric mucus/gel-forming) [NCBI Gene 4583] {aka MLP, MUC-2, SMUC}, Ocln (occludin) [NCBI Gene 18260] {aka Ocl}, Casp1 (caspase 1) [NCBI Gene 12362] {aka ICE, Il1bc}
- **Diseases:** Gut dysfunction (MESH:C535334), Inflammatory (MESH:D007249), motor deficits (MESH:D009461), gliosis (MESH:D005911), Lewy (MESH:D018827), GI dysfunction (MESH:D005767), dopaminergic (MESH:D009422), CNS dysfunction (MESH:D002493), OA (MESH:D010003), neurodegeneration (MESH:D019636), dysbiosis (MESH:D064806), PD (MESH:D010300), neuroinflammation (MESH:D000090862), constipation (MESH:D003248), intestinal barrier dysfunction (MESH:D007410)
- **Chemicals:** DTT (MESH:D004229), dextran (MESH:D003911), SCFA (MESH:D005232), sodium pyrophosphate (MESH:C003319), glucose (MESH:D005947), MPTP (MESH:D015632), NaCl (MESH:D012965), LPS (MESH:D008070), Tween 20 (MESH:D011136), NaHCO3 (MESH:D017693), CO2 (MESH:D002245), Hematoxylin (MESH:D006416), H&amp;E (MESH:D006371), NaF (MESH:D012969), FITC-dextran (MESH:C015219), Alcian blue (MESH:D000423), xylazine (MESH:D014991), paraffin (MESH:D010232), CaCl2 (MESH:D002122), mannitol (MESH:D008353), EDTA (MESH:D004492), agar (MESH:D000362), Rotenone (MESH:D012402), eosin (MESH:D004801), benzamidine (MESH:C032157), SDS (MESH:D012967), leupeptin (MESH:C032854), 6-OHDA (MESH:D016627), Triton X-100 (MESH:D017830), O2 (MESH:D010100), KCl (MESH:D011189), PVDF (MESH:C024865), sodium deoxycholate (MESH:D003840), carbogen (MESH:C011700), agarose (MESH:D012685), Alexa (-), serine (MESH:D012694), MgSO4 (MESH:D008278)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** A53T

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13009022/full.md

---
Source: https://tomesphere.com/paper/PMC13009022